Drug Profile


Alternative Names: IW-1973; sGC agonist-Ironwood

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ironwood Pharmaceuticals
  • Class Cardiovascular therapies
  • Mechanism of Action Soluble guanylyl cyclase agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cardiovascular disorders; Diabetic nephropathies; Heart failure; Hypertension in diabetes
  • Phase I Pulmonary arterial hypertension

Most Recent Events

  • 12 Apr 2018 Ironwood Pharmaceuticals plans a phase I trial for Healthy volunteers in USA (NCT03499106)
  • 04 Dec 2017 Safety, efficacy and pharmacodynamic data from phase IIa trials in Hypertension in diabetes released by Ironwood Pharmaceuticals
  • 02 Nov 2017 Phase-II clinical trials in Diabetic nephropathy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top